Abstract:Abstract Background Osteosarcoma is the most common malignant primary bone tumor in infants and adolescents. The lack of understanding of the molecular mechanisms underlying osteosarcoma progression and metastasis has contributed to a plateau in the development of current therapies. Endoplasmic reticulum (ER) stress has emerged as a significant contributor to the malignant progression of tumors, but its potential regulatory mechanisms in osteosarcoma progression remain unknown. Methods In this study, we collected RNA sequencing and clinical data of osteosarcoma from The TCGA, GSE21257, and GSE33382 cohorts. Differentially expressed analysis and the least absolute shrinkage and selection operator regression analysis were conducted to identify prognostic genes and construct an ER stress-related prognostic signature (ERSRPS). Survival analysis and time dependent ROC analysis were performed to evaluate the predictive performance of the constructed prognostic signature. The “ESTIMATE” package and ssGSEA algorithm were utilized to evaluate the differences in immune cells infiltration between the groups. Cell-based assays, including CCK-8, colony formation, and transwell assays and co-culture system were performed to assess the effects of the target gene and small molecular drug in osteosarcoma. Animal models were employed to assess the anti-osteosarcoma effects of small molecular drug. Results Five genes (BLC2, MAGEA3, MAP3K5, STC2, TXNDC12) were identified to construct an ERSRPS. The ER stress-related gene Stanniocalcin 2 (STC2) was identified as a risk gene in this signature. Additionally, STC2 knockdown significantly inhibited osteosarcoma cell proliferation, migration, and invasion. Furthermore, the ER stress-related gene STC2 was found to downregulate the expression of MHC-I molecules in osteosarcoma cells, and mediate immune responses through influencing the infiltration and modulating the function of CD8+ T cells. Patients categorized by risk scores showed distinct immune status, and immunotherapy response. ISOX was subsequently identified and validated as an effective anti-osteosarcoma drug through a combination of CMap database screening and in vitro and in vivo experiments. Conclusion The ERSRPS may guide personalized treatment decisions for osteosarcoma, and ISOX holds promise for repurposing in osteosarcoma treatment.

Identification of DDX5 as a Potential Therapeutic Target of Osteosarcoma Using Thiazolone Probes

Zinc finger Asp-His-His-Cys palmitoyl -acyltransferase 19 accelerates tumor progression through wnt/β-catenin pathway and is upregulated by miR-940 in osteosarcoma

Novel 2-Phenyl-3-(pyridin-2-yl) Thiazolidin-4-one Derivatives As Potent Inhibitors for Proliferation of Osteosarcoma Cells in Vitro and in Vivo

Identification of therapeutic targets for osteosarcoma by integrating single-cell RNA sequencing and network pharmacology

Identification of Tumorigenicity-Associated Genes in Osteosarcoma Cell Lines Based on Bioinformatic Analysis and Experimental Validation.

Identification of XD23 as a potent inhibitor of osteosarcoma via downregulation of DKK1 and activation of the WNT/β-catenin pathway

Identification and experimental validation of Stearoyl-CoA desaturase is a new drug therapeutic target for osteosarcoma

Cyclovirobuxine D Inhibits the Growth of Osteosarcoma Cells Through the Induction of Autophagy Flux Arrest by Promoting Lysosomal Acidification

Prediction and Identification of GPCRs Targeting for Drug Repurposing in Osteosarcoma

Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma

Discovery of potent thiazolidin-4-one sulfone derivatives for inhibition of proliferation of osteosarcoma in vitro and in vivo

Potential Mechanisms and Indication of Candidate Therapeutic Targets

Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment

Targeting the Anaphase-Promoting Complex/cyclosome (APC/C)- Bromodomain Containing 7 (BRD7) Pathway for Human Osteosarcoma

Proteomic Identification Of Osteosarcoma-Derived Exosomes And Their Activation Of Pentose Phosphate Pathway

DNA Damage Response Genes in Osteosarcoma

Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment

Transcriptome Analysis Identifies Novel Prognostic Genes in Osteosarcoma

Identification of a novel MYC target gene set signature for predicting the prognosis of osteosarcoma patients

Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma

Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma